Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Clean Super Vaccine
- Development stage
- Unknown
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Clean Super Vaccine is an autologous, personalized dendritic cell-based vaccine developed by Aivita Biomedika for the prevention of multiple infectious diseases. The platform utilizes a patient's own dendritic cells, which are harvested and loaded with antigens from various pathogens to induce a robust and long-lasting adaptive T-cell immune response. This rapidly scalable approach is designed to provide broad protection against multiple viral and bacterial agents—including COVID-19, Ebola, and Influenza—within a single injection, while minimizing adverse events by using the patient's own antigen-presenting cells. The vaccine has been validated in vitro for immune responses against a wide range of pathogens and has reached Phase 2 clinical testing for COVID-19.
- Brand names
- The Clean Super Vaccine
- Other names
- Multi-pathogen prevention vaccineAIVITA multi-pathogen vaccine
Beyond the preview
Go deeper on The Clean Super Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on The Clean Super Vaccine.